{"disease":{"id":"pai-n","name":"pai n"},"drugs":{"marketed":[{"drug_id":"buprenorphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"relugolix","indication_name":"Lower abdominal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orgovyx","generic_name":"relugolix","company_name":"MYOVANT SCIENCES","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist [EPC]","quality_score":72,"revenue":"421","mechanism":"Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors."},{"drug_id":"relugolix","indication_name":"Pain associated with endometriosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orgovyx","generic_name":"relugolix","company_name":"MYOVANT SCIENCES","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist [EPC]","quality_score":72,"revenue":"421","mechanism":"Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors."},{"drug_id":"mirogabalin","indication_name":"Peripheral neuropathic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tarlige","generic_name":"MIROGABALIN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel subunit alpha-2/delta-1","drug_class":"","quality_score":35,"revenue":"300","mechanism":""},{"drug_id":"naloxone","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Narcan","generic_name":"NALOXONE","company_name":"Adapt","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"mer","indication_name":"Minor Joint Pain or Stiffness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"orphenadrine","indication_name":"Acute painful musculoskeletal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"cesium","indication_name":"Nerve pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurotox","generic_name":"CESIUM","company_name":"BioActive Nutritional, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"belladonna","indication_name":"Swimmer's ear pain or itching","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hylands Naturals Earache Drops","generic_name":"BELLADONNA","company_name":"Hyland's Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"belladonna","indication_name":"Ear pain or itching from other earaches","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hylands Naturals Earache Drops","generic_name":"BELLADONNA","company_name":"Hyland's Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"platinum","indication_name":"Pain relief after dental procedures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dentastat","generic_name":"PLATINUM","company_name":"Energique, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"apap","indication_name":"Arthritis Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated","generic_name":"APAP","company_name":"HF Acquisition Co LLC, DBA HealthFirst","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"calendula","indication_name":"Muscular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calendula","company_name":"Stratpharma AG","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"calendula","indication_name":"Joint Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calendula","company_name":"Stratpharma AG","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"calendula","indication_name":"Back Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calendula","company_name":"Stratpharma AG","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"calendula","indication_name":"Nerve Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calendula","company_name":"Stratpharma AG","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"calendula","indication_name":"Arthritis Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calendula","company_name":"Stratpharma AG","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"methadone","indication_name":"Severe and Persistent Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"levorphanol","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levo-Dromoran","generic_name":"LEVORPHANOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":64,"revenue":null,"mechanism":"Levorphanol binds primarily to mu-opioid receptors to produce analgesia, with no ceiling effect for pain relief."},{"drug_id":"levomenthol","indication_name":"Pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salonpas","generic_name":"LEVOMENTHOL","company_name":"","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 8","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"citric-acid","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"CITRIC ACID","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Anti-coagulant","quality_score":50,"revenue":null,"mechanism":"Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones."},{"drug_id":"lecithin","indication_name":"Painful Calves Upon Walking Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LECITHIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"pentazocine","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENTAZOCINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"nalbuphine-hydrochloride","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NALBUPHINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"kappa opioid receptors, mu opioid receptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Nalbuphine activates kappa opioid receptors and blocks mu opioid receptors."},{"drug_id":"oxymorphone","indication_name":"Acute Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"pentazocine-hydrochloride","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENTAZOCINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"meperidine","indication_name":"Acute Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEPERIDINE","company_name":"","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"opioid analgesic","quality_score":10,"revenue":null,"mechanism":"Meperidine is an opioid agonist that binds to mu-opioid receptors to produce analgesia and sedation."},{"drug_id":"triprolidine","indication_name":"Minor aches and pains relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"meclofenamic-acid","indication_name":"Mild to Moderate Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclofenamate","generic_name":"MECLOFENAMIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"meclofenamic acid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"meclofenamic-acid","indication_name":"Acute Painful Shoulder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclofenamate","generic_name":"MECLOFENAMIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"meclofenamic acid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fenoprofen-calcium","indication_name":"Mild to Moderate Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FENOPROFEN CALCIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"sodium-sulfate","indication_name":"Migraine headache pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"sodium-sulfate","indication_name":"Headache pain with nausea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"nsaids-ibubrofen-aspirin","indication_name":"Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NSAIDs \"ibubrofen,Aspirin\"","company_name":"Assiut University","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"dextromethorphan-hydrobromide","indication_name":"Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROMETHORPHAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Expectorant [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1718","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NALOXONE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"xzp-5610-tablet-for-part-c2","indication_name":"Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"XZP-5610 Tablet for \"Part C2\"","company_name":"Xuanzhu Biopharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"ziconotide-acetate","indication_name":"Severe Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ZICONOTIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":32,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103744","indication_name":"Acute Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MORPHINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103744","indication_name":"Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MORPHINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"eucalyptus-oil","indication_name":"Muscle and joint pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"EUCALYPTUS OIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"multiple-visit-corticosteroid-paste","indication_name":"Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Multiple-Visit-\"Corticosteroid Paste\"","company_name":"Istanbul Medipol University Hospital","drug_phase":"marketed","molecular_target":"cyclooxygenase (COX-1 and COX-2)","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":"Naproxen reduces pain, inflammation, and fever by inhibiting prostaglandin synthesis through COX-1 and COX-2 inhibition."},{"drug_id":"belladonna-and-opium","indication_name":"Ureteral Spasm Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Belladonna and Opium","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Belladonna/opium rectal suppository combines atropine and morphine to relax smooth muscles and increase pain threshold, respectively."},{"drug_id":"antipyrine","indication_name":"Jaw Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ANTIPYRINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"butorphanol-tartrate","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUTORPHANOL TARTRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"valeriana-officinalis","indication_name":"Painful Calves Upon Walking Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valeriana officinalis","company_name":"Millet Roux","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"bromfenac-ophthalmic-solution","indication_name":"Postoperative inflammation and ocular pain after cataract surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"bromfenac ophthalmic solution","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"ethacrynic-acid","indication_name":"Impaired Gastrointestinal Absorption","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"xibrom","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xibrom","company_name":"Bp Consulting, Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenylmercuric-nitrate","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenylmercuric nitrate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"phenylmercuric nitrate","quality_score":null,"revenue":null,"mechanism":"Phenylmercuric nitrate works by releasing mercury ions that have antimicrobial and anti-inflammatory properties."},{"drug_id":"magnesium-salicylate","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Magan","generic_name":"magnesium salicylate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium salicylate","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"magnesium-salicylate","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Magan","generic_name":"magnesium salicylate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium salicylate","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"levomenthol","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salonpas","generic_name":"LEVOMENTHOL","company_name":"","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 8","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"levomenthol","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salonpas","generic_name":"LEVOMENTHOL","company_name":"","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 8","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"celecoxib","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celebrex","generic_name":"celecoxib","company_name":"Pfizer Inc. (originally Searle/Pharmacia)","drug_phase":"marketed","molecular_target":"COX-2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Celecoxib works by inhibiting COX-2 to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever."},{"drug_id":"ferric-oxide","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iron Oxide","generic_name":"ferric oxide","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"dexibuprofen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXIBUPROFEN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"dexibuprofen","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"choline-magnesium-trisalicylate","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilisate","generic_name":"CHOLINE MAGNESIUM TRISALICYLATE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"choline magnesium trisalicylate","quality_score":null,"revenue":null,"mechanism":"Trilisate works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation."},{"drug_id":"allantoin","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allantol","generic_name":"ALLANTOIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"allantoin","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"diamorphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heroin","generic_name":"diamorphine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"Opioid Agonist","quality_score":null,"revenue":null,"mechanism":"Heroin works by binding to opioid receptors in the brain, mimicking the action of natural pain-relieving chemicals."},{"drug_id":"dextropropoxyphene","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propoxyphene Compound 65","generic_name":"dextropropoxyphene","company_name":"","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"sulfentanyl","indication_name":"Postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfentanyl","company_name":"Shenzhen Third People's Hospital","drug_phase":"phase_1","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":32,"revenue":null,"mechanism":null},{"drug_id":"danuglipron","indication_name":"Treatment of acute and chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Danuglipron","generic_name":"danuglipron","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":49,"revenue":null,"mechanism":"Danuglipron is a small-molecule GLP-1 receptor agonist."},{"drug_id":"lyrica","indication_name":"Neuropathic pain associated with diabetic peripheral neuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"lyrica","indication_name":"Neuropathic pain associated with spinal cord injury","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"fenoprofen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nalfon","generic_name":"FENOPROFEN","company_name":"Pharmaco","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocodone","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"HYDROCODONE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":67,"revenue":null,"mechanism":"Tussionex Pennkinetic works by binding to opioid receptors in the brain, which helps to reduce pain and congestion."},{"drug_id":"ropivacaine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Naropin","generic_name":"ROPIVACAINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"ropivacaine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Naropin","generic_name":"ROPIVACAINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cesium","indication_name":"nerve pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurotox","generic_name":"CESIUM","company_name":"BioActive Nutritional, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"yellox","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yellox","company_name":"University of Trieste","drug_phase":"phase_3","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"yellox","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yellox","company_name":"University of Trieste","drug_phase":"phase_3","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"platinum","indication_name":"pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dentastat","generic_name":"PLATINUM","company_name":"Energique, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"gadolinium","indication_name":"nerve pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurotox","generic_name":"GADOLINIUM","company_name":"BioActive Nutritional, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"etoxazene","indication_name":"Urinary tract pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamazol","generic_name":"etoxazene","company_name":"Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"dihydrocodeine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synalgos-Dc","generic_name":"DIHYDROCODEINE","company_name":"Caraco","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"belladonna","indication_name":"common pain or itching from swimmer’s ear","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hylands Naturals Earache Drops","generic_name":"BELLADONNA","company_name":"Hyland's Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"belladonna","indication_name":"ear pain or itching from other earaches","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hylands Naturals Earache Drops","generic_name":"BELLADONNA","company_name":"Hyland's Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"apap","indication_name":"minor pain of arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated","generic_name":"APAP","company_name":"HF Acquisition Co LLC, DBA HealthFirst","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"borneol","indication_name":"pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hemorrhoid, Fissure, ProctalgiaSuppositories","generic_name":"BORNEOL","company_name":"WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Chemical Allergen [EPC]","quality_score":28,"revenue":null,"mechanism":"Proctalgia Suppositories works by interacting with the anal tissue to reduce symptoms of irritation, pain, and discomfort."},{"drug_id":"clonidine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"tramadol","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultram","generic_name":"tramadol","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tramadol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultram","generic_name":"tramadol","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"methocarbamol","indication_name":"Muscle Spasm with Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Robaxin","generic_name":"METHOCARBAMOL","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Muscle Relaxant [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"diclofenac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voltaren","generic_name":"DICLOFENAC","company_name":"Hisamitsu Pharmaceutical Co., Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"diclofenac","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voltaren","generic_name":"DICLOFENAC","company_name":"Hisamitsu Pharmaceutical Co., Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"naloxone","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Narcan","generic_name":"NALOXONE","company_name":"Adapt","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oliceridine","indication_name":"Moderate pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olinvyk","generic_name":"OLICERIDINE","company_name":"Trevena","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain."},{"drug_id":"oliceridine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olinvyk","generic_name":"OLICERIDINE","company_name":"Trevena","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain."},{"drug_id":"duloxetine","indication_name":"Chronic Musculoskeletal Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cymbalta","generic_name":"duloxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin and norepinephrine reuptake inhibitor (SNRI)","quality_score":68,"revenue":null,"mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms."},{"drug_id":"cortisone","indication_name":"muscle pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immune Support","generic_name":"CORTISONE","company_name":"Merck","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"butamben","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butesin","generic_name":"BUTAMBEN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":10,"revenue":null,"mechanism":"Butesin works by interacting with the nervous system to reduce pain and itching sensations."},{"drug_id":"bupivacaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"BUPIVACAINE","company_name":"Innocoll","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"Amide Local Anesthetic","quality_score":69,"revenue":null,"mechanism":"Bupivacaine works by blocking nerve impulses to prevent pain signals from reaching the brain."},{"drug_id":"bupivacaine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"BUPIVACAINE","company_name":"Innocoll","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"Amide Local Anesthetic","quality_score":69,"revenue":null,"mechanism":"Bupivacaine works by blocking nerve impulses to prevent pain signals from reaching the brain."},{"drug_id":"bupivacaine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"BUPIVACAINE","company_name":"Innocoll","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"Amide Local Anesthetic","quality_score":69,"revenue":null,"mechanism":"Bupivacaine works by blocking nerve impulses to prevent pain signals from reaching the brain."},{"drug_id":"suzetrigine","indication_name":"moderate to severe acute pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Journavx","generic_name":"SUZETRIGINE","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Sodium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":"Journavx blocks sodium channels in the nervous system to reduce pain signal transmission."},{"drug_id":"suzetrigine","indication_name":"postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Journavx","generic_name":"SUZETRIGINE","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Sodium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":"Journavx blocks sodium channels in the nervous system to reduce pain signal transmission."},{"drug_id":"caffeine","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trometamol","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tham","generic_name":"trometamol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"trometamol","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"simetride","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIMETRIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"lornoxicam","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorcam","generic_name":"LORNOXICAM","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"lornoxicam","quality_score":0,"revenue":null,"mechanism":"Lorcam works by blocking the COX-2 enzyme, which reduces the production of prostaglandins that cause pain and inflammation."},{"drug_id":"alclofenac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reufenac","generic_name":"ALCLOFENAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"alclofenac","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Breakthrough cancer pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"emorfazone","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandron","generic_name":"EMORFAZONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"emorfazone","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Postoperative ocular pain in intraocular lens replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"camphor","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphanon","generic_name":"CAMPHOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"camphor","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"difluprednate","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Durezol","generic_name":"DIFLUPREDNATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"difluprednate","quality_score":51,"revenue":null,"mechanism":"Durezol works by binding to glucocorticoid receptors in the body, mimicking the effects of cortisol to reduce inflammation."},{"drug_id":"lopid","indication_name":"Treatment of adult patients with triglyceride elevations between 1,000-2,000 mg/dL and history of pancreatitis or recurrent abdominal pain typical of pancreatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Postoperative ocular pain in intraocular lens replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with impaired renal function.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"capsaicin","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qutenza","generic_name":"CAPSAICIN","company_name":"Averitas","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"capsaicin","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"valdecoxib","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valecoxib","generic_name":"VALDECOXIB","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"valdecoxib","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"pramiracetam","indication_name":"Memory impairment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amacetam","generic_name":"PRAMIRACETAM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"pramiracetam","quality_score":null,"revenue":null,"mechanism":"Pramiracetam works by increasing the activity of certain neurotransmitters in the brain, such as acetylcholine, to enhance memory and cognitive function."},{"drug_id":"bat","indication_name":"Treatment of neuropathic pain associated with diabetic peripheral neuropathy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"oxycodone","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"oxycodone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"oxycodone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"naloxone-hydrochloride","indication_name":"Management of pain severe enough to require an opioid analgesic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options are ineffective","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options are not tolerated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options would be otherwise inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naltrexon","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pethidine","indication_name":"Labor pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pethidine","company_name":"","drug_phase":"unknown","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pethidine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pethidine","company_name":"","drug_phase":"unknown","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pethidine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pethidine","company_name":"","drug_phase":"unknown","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bupivacain","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupivacain","company_name":"Sisli Hamidiye Etfal Training and Research Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bupivacain","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupivacain","company_name":"Sisli Hamidiye Etfal Training and Research Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bupivacain","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupivacain","company_name":"Sisli Hamidiye Etfal Training and Research Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"clonidin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Local Anesthesia for Urethral Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"codeine","indication_name":"Muscle Spasm with Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"codeine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carisoprodol","indication_name":"Muscle Spasm with Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Soma","generic_name":"CARISOPRODOL","company_name":"Mylan Speciality Lp","drug_phase":"marketed","molecular_target":"","drug_class":"Muscle Relaxant [EPC]","quality_score":59,"revenue":null,"mechanism":"Carisoprodol's mechanism for relieving acute musculoskeletal pain is unclear, but it involves altered interneuronal activity in the spinal cord and brain."},{"drug_id":"ropivacain","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ropivacain","company_name":"University Hospital, Basel, Switzerland","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ropivacain","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ropivacain","company_name":"University Hospital, Basel, Switzerland","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naropine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropine","company_name":"Rigshospitalet, Denmark","drug_phase":"phase_1","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naropine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropine","company_name":"Rigshospitalet, Denmark","drug_phase":"phase_1","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neomycin","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"methadone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"lidocaine-hydrochloride","indication_name":"Local Anesthesia for Urethral Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"lidocaine-hydrochloride","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"felbinac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Traxam","generic_name":"FELBINAC","company_name":"","drug_phase":"phase_3","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"felbinac","quality_score":null,"revenue":null,"mechanism":"Traxam works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation."},{"drug_id":"parecoxib","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xapit","generic_name":"PARECOXIB","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"parecoxib","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tiquizium","indication_name":"Abdominal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thiaton","generic_name":"TIQUIZIUM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"tiquizium","quality_score":null,"revenue":null,"mechanism":"Thiaton works by interacting with a specific molecular target to reduce pain signals in the body."},{"drug_id":"benzydamine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzidamine","generic_name":"BENZYDAMINE","company_name":"","drug_phase":"phase_3","molecular_target":"Soluble guanylate cyclase","drug_class":"benzydamine","quality_score":null,"revenue":null,"mechanism":"Benzidamine works by activating soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), leading to pain relief."},{"drug_id":"benzethonium","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzetonium Chloride","generic_name":"BENZETHONIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"benzethonium","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"cinchocaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dibucaine","generic_name":"cinchocaine","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"flufenamic-acid","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluphenamic Acid","generic_name":"FLUFENAMIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"flufenamic acid","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"floctafenine","indication_name":"Acute pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idarac","generic_name":"FLOCTAFENINE","company_name":"","drug_phase":"phase_2","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"floctafenine","quality_score":null,"revenue":null,"mechanism":"Idarac works by blocking the production of prostaglandins, which are chemical messengers that transmit pain signals to the brain."},{"drug_id":"tinoridine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tienoridine","generic_name":"TINORIDINE","company_name":"","drug_phase":"phase_3","molecular_target":"Adenosine receptor A1","drug_class":"tinoridine","quality_score":null,"revenue":null,"mechanism":"Tienoridine works by binding to the adenosine receptor A1, which helps to reduce pain by modulating the activity of neurons."},{"drug_id":"fentiazac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flogene","generic_name":"FENTIAZAC","company_name":"","drug_phase":"phase_2","molecular_target":"Prostaglandin D2 receptor 2","drug_class":"fentiazac","quality_score":null,"revenue":null,"mechanism":"Flogene works by blocking the action of prostaglandin D2, a chemical that transmits pain signals to the brain."},{"drug_id":"dextromoramide","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moramide","generic_name":"DEXTROMORAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"dextromoramide","quality_score":0,"revenue":null,"mechanism":"Dextromoramide works by binding to opioid receptors in the brain, spinal cord, and other areas to produce analgesia and euphoria."},{"drug_id":"dezocine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dalgan","generic_name":"DEZOCINE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"dezocine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"fentanyl","indication_name":"Breakthrough cancer pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"levorphanol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levo-Dromoran","generic_name":"LEVORPHANOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":64,"revenue":null,"mechanism":"Levorphanol binds primarily to mu-opioid receptors to produce analgesia, with no ceiling effect for pain relief."},{"drug_id":"pethidin","indication_name":"Labor pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pethidin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pethidin","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pethidin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pethidin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pethidin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"heroin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Heroin","company_name":"MetroHealth Medical Center","drug_phase":"phase_3","molecular_target":"D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naropeine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropeine","company_name":"University Hospital, Rouen","drug_phase":"phase_3","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naropeine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropeine","company_name":"University Hospital, Rouen","drug_phase":"phase_3","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"meptazinol","indication_name":"Moderate pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meptamizol","generic_name":"MEPTAZINOL","company_name":"","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"meptazinol","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"piketoprofen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calmatel","generic_name":"PIKETOPROFEN","company_name":"","drug_phase":"phase_2","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"remifentanyl","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Remifentanyl","company_name":"Kocaeli University","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"morphine","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"ibuprofen","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"ibuprofen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"ibuprofen","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"acetylsalicylic-acid","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"acetylsalicylic-acid","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"acetylsalicylic-acid","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"meperidine","indication_name":"Acute pain management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEPERIDINE","company_name":"","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"opioid analgesic","quality_score":10,"revenue":null,"mechanism":"Meperidine is an opioid agonist that binds to mu-opioid receptors to produce analgesia and sedation."},{"drug_id":"mer","indication_name":"Temporary relief of minor joint pain or stiffness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dyclonine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dyclone","generic_name":"DYCLONINE","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"dyclonine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlorzoxazone","indication_name":"Muscle Spasm with Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parafon Forte Dsc","generic_name":"CHLORZOXAZONE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, endothelial","drug_class":"Muscle Relaxant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"methyl-salicylate","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salonpas","generic_name":"METHYL SALICYLATE","company_name":"Hisamitsu Pharm Co","drug_phase":"marketed","molecular_target":"","drug_class":"methyl salicylate","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"methyl-nicotinate","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methyl 3-Pyridinecarboxylate","generic_name":"methyl nicotinate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"methyl nicotinate","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"paracetamol","indication_name":"Arthritic Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"paracetamol","indication_name":"Pain Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"demerol","indication_name":"Labor pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meperidine Hydrochloride Preservative Free","generic_name":"Meperidine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":72,"revenue":null,"mechanism":"Meperidine Hydrochloride Preservative Free works by binding to opioid receptors in the brain, altering the perception of and response to pain."},{"drug_id":"demerol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meperidine Hydrochloride Preservative Free","generic_name":"Meperidine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":72,"revenue":null,"mechanism":"Meperidine Hydrochloride Preservative Free works by binding to opioid receptors in the brain, altering the perception of and response to pain."},{"drug_id":"demerol","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meperidine Hydrochloride Preservative Free","generic_name":"Meperidine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":72,"revenue":null,"mechanism":"Meperidine Hydrochloride Preservative Free works by binding to opioid receptors in the brain, altering the perception of and response to pain."},{"drug_id":"diflunisal","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dolobid","generic_name":"DIFLUNISAL","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"diflunisal","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dolobid","generic_name":"DIFLUNISAL","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ketorolac","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toradol","generic_name":"KETOROLAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Cyclooxygenase Inhibitor","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ketorolac","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toradol","generic_name":"KETOROLAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Cyclooxygenase Inhibitor","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ketorolac","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toradol","generic_name":"KETOROLAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Cyclooxygenase Inhibitor","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"bromfenac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xibrom","generic_name":"BROMFENAC","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":80,"revenue":null,"mechanism":"Xibrom works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation."},{"drug_id":"bromfenac","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xibrom","generic_name":"BROMFENAC","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":80,"revenue":null,"mechanism":"Xibrom works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation."},{"drug_id":"ketoprofen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orudis","generic_name":"KETOPROFEN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"etodolac","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lodine","generic_name":"ETODOLAC","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"arthrotec","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arthrotec","generic_name":"Diclofenac Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acid-sensing ion channel 3","drug_class":"diclofenac","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"arthrotec","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arthrotec","generic_name":"Diclofenac Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acid-sensing ion channel 3","drug_class":"diclofenac","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"neurontin","indication_name":"Neuropathic pain associated with spinal cord injury","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"codeine","indication_name":"Mild to Moderate Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"neurontin","indication_name":"Chronic low back pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"neurontin","indication_name":"Pain associated with fibromyalgia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"morphine-sulfate","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"vaccination","indication_name":"injection site pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Post - Vaccination","generic_name":"vaccination","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"Inactivated Poliovirus Vaccine [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"morphine-sulfate","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Labor pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"sufentanil","indication_name":"Postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sufenta Preservative Free","generic_name":"SUFENTANIL","company_name":"Rising","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Sufentanil works by binding to opioid receptors in the brain, spinal cord, and other areas to produce pain relief."},{"drug_id":"maltodextrin","indication_name":"abdominal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aspartame/MSG Detox","generic_name":"MALTODEXTRIN","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"flavoxate","indication_name":"Suprapubic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Urispas","generic_name":"FLAVOXATE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"propoxyphene","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propoxyphene Compound 65","generic_name":"PROPOXYPHENE","company_name":"","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 3A","drug_class":"Opioid Agonist","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"benzalkonium","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzododecinium","generic_name":"BENZALKONIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"benzalkonium","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"benzocaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norcaine","generic_name":"BENZOCAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"levobupivacaine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chirocain","generic_name":"LEVOBUPIVACAINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"levobupivacaine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"levobupivacaine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chirocain","generic_name":"LEVOBUPIVACAINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"levobupivacaine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nepafenac","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nevanac","generic_name":"NEPAFENAC","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":75,"revenue":null,"mechanism":"Nevanac works by inhibiting the enzyme prostaglandin G/H synthase 2, which is involved in producing prostaglandins that cause pain and inflammation."},{"drug_id":"amifostine","indication_name":"Prevention of Cancer Chemotherapy-Induced Renal Impairment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ethyol","generic_name":"AMIFOSTINE","company_name":"Cosette","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"amifostine","quality_score":75,"revenue":null,"mechanism":"Ethyol works by protecting the kidneys and salivary glands from damage caused by chemotherapy and radiation."},{"drug_id":"meclofenamic-acid","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclofenamate","generic_name":"MECLOFENAMIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"meclofenamic acid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"terbutaline","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"butorphanol","indication_name":"Labor pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stadol Preservative Free","generic_name":"BUTORPHANOL","company_name":"","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Opioid Agonist/Antagonist","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"butorphanol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stadol Preservative Free","generic_name":"BUTORPHANOL","company_name":"","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Opioid Agonist/Antagonist","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"tapentadol","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nucynta","generic_name":"TAPENTADOL","company_name":"Collegium Pharm Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":75,"revenue":null,"mechanism":"Nucynta works by binding to opioid receptors in the brain to reduce the perception of pain."},{"drug_id":"zinc-acetate","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Galzin","generic_name":"ZINC ACETATE","company_name":"Eton","drug_phase":"marketed","molecular_target":"","drug_class":"zinc acetate","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"nepa","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NEPA","company_name":"Harrow Eye","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"tetracaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tetracaine Hydrochloride","generic_name":"TETRACAINE","company_name":"Alcon Labs","drug_phase":"marketed","molecular_target":"Sodium channel protein type 7 subunit alpha","drug_class":"Ester Local Anesthetic","quality_score":10,"revenue":null,"mechanism":"Tetracaine Hydrochloride works by blocking sodium channels in nerve cells to prevent pain signals from being transmitted."},{"drug_id":"oxycontin","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"oxycontin","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"oxycontin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"sama","indication_name":"Pain due to Osteoblastic Bone Metastasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMA","company_name":"Lantheus Medical","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Sama is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect."},{"drug_id":"xibrom","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xibrom","company_name":"Bp Consulting, Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Rectal pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"resorcinol","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"resorcinol","company_name":"","drug_phase":"unknown","molecular_target":"Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"celebrex","indication_name":"Acute postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"celebrex","company_name":"POZEN","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Local Anesthesia for Urethral Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methadon","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methadon","company_name":"University of Utah","drug_phase":"discontinued","molecular_target":"Neuronal acetylcholine receptor subunit alpha-10, D(4) dopamine receptor, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"vioxx","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vioxx","company_name":"M.D. Anderson Cancer Center","drug_phase":"discontinued","molecular_target":"Cytochrome c oxidase subunit 2, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"sulfentanil","indication_name":"Postoperative pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfentanil","company_name":"Henan Provincial People's Hospital","drug_phase":"phase_1","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nevanac","indication_name":"Postoperative Ocular Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nevanac","company_name":"Santa Casa de Misericordia de Santos","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Local Anesthesia for Urethral Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"meclofenamate","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Meclofenamate","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naproxen","indication_name":"Joint pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"naproxen","indication_name":"Muscle pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"naproxen","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"tilidine","indication_name":"Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tilidate","generic_name":"TILIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bupivacaine-hydrochloride-and-epinephrine","indication_name":"Minor Skin Wound Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride","generic_name":"Bupivacaine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nerve sodium channels","drug_class":"Amide-type local anesthetic","quality_score":10,"revenue":null,"mechanism":"Bupivacaine blocks nerve impulse generation and conduction by increasing electrical excitation threshold and slowing action potential rise."},{"drug_id":"bupivacaine-hydrochloride-and-epinephrine","indication_name":"Regional Anesthesia for Labor Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride","generic_name":"Bupivacaine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nerve sodium channels","drug_class":"Amide-type local anesthetic","quality_score":10,"revenue":null,"mechanism":"Bupivacaine blocks nerve impulse generation and conduction by increasing electrical excitation threshold and slowing action potential rise."},{"drug_id":"bupivacaine-hydrochloride-and-epinephrine","indication_name":"Regional Anesthesia for Postoperative Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride","generic_name":"Bupivacaine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nerve sodium channels","drug_class":"Amide-type local anesthetic","quality_score":10,"revenue":null,"mechanism":"Bupivacaine blocks nerve impulse generation and conduction by increasing electrical excitation threshold and slowing action potential rise."},{"drug_id":"neurontin","indication_name":"Phantom limb pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"magnesium-salicylate","indication_name":"Minor backache pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Magan","generic_name":"magnesium salicylate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium salicylate","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"calcium-hydrogen-phosphate-dihydrate","indication_name":"Minor Tooth Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dibasic Calcium Phosphate Dihydrate","generic_name":"calcium hydrogen phosphate dihydrate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"same","indication_name":"Mild Muscle Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMe","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Methyltransferases","drug_class":"Vitamin B12 [EPC]","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"same","indication_name":"Mild Joint Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMe","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Methyltransferases","drug_class":"Vitamin B12 [EPC]","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"lysine","indication_name":"Painful skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"L-Lysine","generic_name":"LYSINE","company_name":"Advanced Accelerator Applications","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"lysine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"dihydrocodeine","indication_name":"Moderate to moderately severe pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synalgos-Dc","generic_name":"DIHYDROCODEINE","company_name":"Caraco","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"lyrica","indication_name":"Neuropathic pain associated with diabetic peripheral neuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"lyrica","indication_name":"Neuropathic pain associated with spinal cord injury","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"camphor","indication_name":"Muscle and joint pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphanon","generic_name":"CAMPHOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"camphor","quality_score":16,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"valacyclovir","indication_name":"Mild Cognitive Impairment","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."}],"offLabel":[],"totalMarketed":333,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07247669","title":"Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000000,"lead_sponsor_name":"Centro de Emergencias Sanitarias 061 Andalucía","has_results":false},{"nct_id":"NCT04053335","title":"Smarter Care Virginia, Examining Low-Value Care in Virginia","phase":"","overall_status":"COMPLETED","enrollment_count":5000000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT03455478","title":"Shanghai Eye Study for Adults","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT05520931","title":"Pain-related Long Covid in Covid-19 Survivors","phase":"","overall_status":"UNKNOWN","enrollment_count":600000,"lead_sponsor_name":"Aalborg University","has_results":false},{"nct_id":"NCT06494670","title":"Trends in Prevalence of 11 Site-specific Musculoskeletal Pain Among U.S. Adults, 1999-2018","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":565219,"lead_sponsor_name":"Fan luying","has_results":false},{"nct_id":"NCT03825991","title":"Psychiatric Comorbidity in Back Pain Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":500000,"lead_sponsor_name":"Spine Centre of Southern Denmark","has_results":false},{"nct_id":"NCT05443503","title":"Stanford Spine Keeper - Managing Your Low Back Pain","phase":"NA","overall_status":"SUSPENDED","enrollment_count":500000,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT06240533","title":"Implementation of P3C-LBP in Swedish Primary Care","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300000,"lead_sponsor_name":"Linkoeping University","has_results":false},{"nct_id":"NCT02015455","title":"Trial of Inserting Prevalence Information Into Lumbar Spine Imaging Reports","phase":"NA","overall_status":"COMPLETED","enrollment_count":250401,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06090578","title":"TabCAT Brain Health Assessment in Primary Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":180000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05745129","title":"Applying Artificial Intelligence in Developing Personalized and Sustainable Healthcare for Spinal Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":165000,"lead_sponsor_name":"Oslo Metropolitan University","has_results":false},{"nct_id":"NCT03971344","title":"Impact of Serious Pediatric Illness on Parent and Sibling Health","phase":"","overall_status":"COMPLETED","enrollment_count":161000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT04701177","title":"Digitally-enhanced, Decentralized, Multi-omics Observational Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Greece 2021 Committee","has_results":false},{"nct_id":"NCT03653156","title":"China Cognition and Aging Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT04839848","title":"Chronic Postoperative Pain After the Lichtenstein Groin Hernioplasty","phase":"","overall_status":"COMPLETED","enrollment_count":80733,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06903624","title":"Cannabis in Postoperative Pain Management","phase":"","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Assuta Medical Center","has_results":false},{"nct_id":"NCT06582407","title":"Machine Learning Models for Predicting Unforeseen Hospital Admissions or Discharges After Anesthesia","phase":"","overall_status":"COMPLETED","enrollment_count":68683,"lead_sponsor_name":"HUmani","has_results":false},{"nct_id":"NCT05649384","title":"Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64374,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT03762174","title":"Characteristics of Back Pain Attendances at ED","phase":"","overall_status":"COMPLETED","enrollment_count":62000,"lead_sponsor_name":"Matt Capsey","has_results":false},{"nct_id":"NCT06692517","title":"Benchmarks in Elective Laparoscopic Cholecystectomy","phase":"","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"Region Östergötland","has_results":false},{"nct_id":"NCT06157112","title":"Students' Lifestyle Behaviour and Later Health Care Utilization Due to Musculoskeletal Pain","phase":"","overall_status":"COMPLETED","enrollment_count":50054,"lead_sponsor_name":"Oslo Metropolitan University","has_results":false},{"nct_id":"NCT04691037","title":"CCTA Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"RIVER Foundation","has_results":false},{"nct_id":"NCT05607732","title":"Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":45257,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05884021","title":"Effectiveness of Pain Control and Adverse Reactions After Intravenous PCA in Chinese Population","phase":"","overall_status":"COMPLETED","enrollment_count":40000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT03760302","title":"Analgesia in ÖAMTC Helicopter Emergency Service in Austria","phase":"","overall_status":"COMPLETED","enrollment_count":35000,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT04488913","title":"Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin","phase":"NA","overall_status":"COMPLETED","enrollment_count":32609,"lead_sponsor_name":"Henry Ford Health System","has_results":false},{"nct_id":"NCT06483022","title":"Building Equitable Linkages With Interprofessional Education Valuing Everyone","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":32000,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03634410","title":"SeniorWorkingLife (Danish Title: SeniorArbejdsLiv)","phase":"","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"National Research Centre for the Working Environment, Denmark","has_results":false},{"nct_id":"NCT05748691","title":"Switching From Cardiac Troponin I to T","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT05058950","title":"An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging","phase":"","overall_status":"TERMINATED","enrollment_count":22720,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT03537573","title":"Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":22616,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT05488080","title":"PAINED: Project Addressing INequities in the Emergency Department","phase":"NA","overall_status":"RECRUITING","enrollment_count":22032,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT05922319","title":"Effects of Training Dose on Computerized Cognitive Training in Patients With Cognitive Impairment","phase":"","overall_status":"COMPLETED","enrollment_count":21845,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05579808","title":"Effect of Epidural Analgesia on Labour, Neonatal and Maternal Outcomes.","phase":"","overall_status":"COMPLETED","enrollment_count":21808,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT05384613","title":"Evaluation of Quality Indicators on Analgesia, Sedation and Delirium in Intensive Care Patients and Their Impact on Outcome Indicators and Economic Indicators","phase":"","overall_status":"COMPLETED","enrollment_count":20220,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT04262206","title":"Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04878562","title":"I-COPE Study: Opioid Use and Pain Management in Older Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06917612","title":"Preserving or Resecting the Normal Appendix in Patients Undergoing Laparoscopy Surgery for Suspected Appendicitis","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT06712264","title":"Construction and Effectiveness Evaluation of Painless Digestive Endoscopy Mode Led by Anesthesia Nurses Under the Guidance of Anesthesiologists","phase":"","overall_status":"COMPLETED","enrollment_count":18000,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT07290361","title":"Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":17587,"lead_sponsor_name":"San Diego State University","has_results":false},{"nct_id":"NCT03421873","title":"Effectiveness and Safety of a Clinical Assessment and 0h/1h Troponin Rule-Out Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":16000,"lead_sponsor_name":"Ulf Ekelund","has_results":false},{"nct_id":"NCT04657159","title":"Health-economic Evaluation of Interventional Pain Management Compared to Pain Rehabilitation","phase":"","overall_status":"COMPLETED","enrollment_count":15611,"lead_sponsor_name":"Eques Indolor AB","has_results":false},{"nct_id":"NCT04838028","title":"Chronic Postoperative Pain After Laparoendoscopic Groin Hernia Repair","phase":"","overall_status":"COMPLETED","enrollment_count":15360,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05765162","title":"Safe Brain Initiative, Operationalizing Precision Anaesthesia","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University of Southern Denmark","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}